Insider

Revolution Medicines, Inc.

RVMD Health Care · 3 analyses · 4 expectations tracked

Insider tracks 4 open management expectations for this company. 3 insider sales recorded. Its latest periodic filing added 47 new risk factors.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Company history

October 2026

Revolution Medicines, Inc.: 12 recorded developments from 10 official sources in 2026-10.

  • 2026-09-18: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-16, 13,988 disposed, total value 2,786,938.39 USD at a weighted average price of 199.2378 USD; owned after the last one: 253,342 Source
  • 2026-09-18: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-16, 4,967 disposed, total value 989,612.58 USD at a weighted average price of 199.2375 USD; owned after the last one: 149,680 Source
  • 2026-09-18: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-16, 5,569 disposed, total value 1,109,554.38 USD at a weighted average price of 199.2376 USD; owned after the last one: 286,307 Source
  • 2026-09-18: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-16, 4,053 disposed, total value 807,513.37 USD at a weighted average price of 199.2384 USD; owned after the last one: 119,216 Source
  • 2026-09-22: Summary: S (open market or private sale): 1 transaction(s) on 2026-09-18, 1,764 disposed, total value 347,402.16 USD at a weighted average price of 196.94 USD; owned after the last one: 40,352 Source
  • 2026-09-24: Summary: S (open market or private sale): 5 transaction(s) on 2026-09-22, 10,143 disposed, total value 1,958,015.88 USD at a weighted average price of 193.0411 USD; owned after the last one: 4,333 Source
  • 2026-09-28: Summary: S (open market or private sale): 2 transaction(s) on 2026-09-24 to 2026-09-25, 3,708 disposed, total value 743,285.34 USD at a weighted average price of 200.4545 USD; owned after the last one: 39,765 Source
  • 2026-09-29: Summary: S (open market or private sale): 1 transaction(s) on 2026-09-25, 765 disposed, total value 158,599.88 USD at a weighted average price of 207.3201 USD; owned after the last one: 51,776 Source
  • 2026-10-01: Summary: S (open market or private sale): 5 transaction(s) on 2026-09-29, 6,309 disposed, total value 1,275,294.23 USD at a weighted average price of 202.1389 USD; owned after the last one: 52,559 Source
  • 2026-10-13: Revolution Medicines, Inc. entered into a Loan Agreement on June 23, 2025, and drew Tranche A of $250.0 million on October 8, 2026, following FDA approval of RASONQUE™. Source
  • 2026-10-13: The Tranche A Loan is a senior secured term loan of up to $250.0 million, interest-only, payable quarterly, with principal due October 8, 2032. Source
  • 2026-10-13: The Company paid the Lender a $5.0 million draw fee upon borrowing the Tranche A Loan. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC

LatestEarlierChange
Revenue quarter$198M$0—
Operating income quarter−$373M−$315M-18.4%
Net income quarter−$407M−$305M-33.5%
Diluted EPS quarter−$1.90−$1.61-18.0%
Operating cash flow year to date−$1.2B−$624M-85.6%
Cash and cash equivalents balance$616M$384M+60.5%

Next results expected around February 3, 2027 (estimate: the quarter ending about December 30, 2026 plus the 35 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $M

0Q3 '230.7Q4 '23*-24,256.5%0Q1 '240Q2 '240Q3 '240Q4 '24*0Q3 '26197.6Q3 '26-188.9%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Revolution Medicines, Inc. RVMD$198M—-188.9%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The company expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design.

    Said November 4, 2026 · Period named: first half of 2027 · Source · Our article

    Not yet checked against later reports.

  • The company remains on track to initiate a first-in-human clinical trial evaluating RM-055.

    Said November 4, 2026 · Period named: fourth quarter of 2026 · Source · Our article

    Not yet checked against later reports.

  • Initial readout for the RASolve 301 trial is anticipated in 2027.

    Said November 4, 2026 · Period named: 2027 · Source · Our article

    Not yet checked against later reports.

  • All sites in the RASolve 301 trial are expected to close enrollment by the end of November 2026.

    Said November 4, 2026 · Period named: end of November 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (47)

  • accurately estimating the rebates, chargebacks, discounts, returns and other deductions that reduce our gross product revenue, and managing the level of those deductions;
  • maintaining adequate commercial supply of RASONQUE to meet demand while avoiding excess or obsolete inventory;
  • exposing us to increases in interest rates, because borrowings under the Term Loan Facility bear interest at a floating rate subject to a floor, such that our interest expense may increase but will not decline below a minimum level;

Dropped (20)

  • funds for our current or future operating plans. See “Item 2. Management’s Discussion and Analysis—Liquidity and Capital Resources” for additional information.
  • obligations. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might otherwise be advantageous to us and our stockholders.
  • The life sciences industry is highly competitive. We are currently developing therapies that will compete, if approved, with other products and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware of. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies,

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 16, 2026Stephen KelseyPlanned sale 10b5-1 plan108,640—$18,717,586SEC
November 11, 2026Jack Lee AndersPlanned sale 10b5-1 plan35,750—$6,901,895SEC
November 11, 2026Jack AndersSale 10b5-1 plan35,750$188.10$6,724,688SEC
November 9, 2026Anthony ManciniSale 10b5-1 plan811$200.00$162,200SEC
October 26, 2026Anthony ManciniSale 10b5-1 plan2,310$186.99$431,947SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
Fidelity (FMR)15,397,714$3,160,534,467+26.2%Q3 2026
BlackRock13,857,324$2,844,354,468+1.2%Q3 2026
State Street5,063,861$1,039,408,109+3.4%Q3 2026
Geode Capital Management4,007,450$832,063,384+1.6%Q3 2026
Wellington Management3,130,941$642,656,949-18.5%Q3 2026
Norges Bank (Norway's sovereign fund)2,157,479$404,052,667—Q2 2026
Citadel Advisors1,310,983$269,092,370+122.2%Q3 2026
Two Sigma Investments91,592$18,800,174-87.6%Q3 2026
Millennium Management81,236$16,674,501-62.4%Q3 2026
D. E. Shaw & Co.766,324$8,782,073-51.9%Q3 2026
Renaissance Technologies6,200$602,950—Q1 2026
T. Rowe Price1,977,484$405,899-17.3%Q3 2026
Duquesne Family Office (Stanley Druckenmiller)436,287$89,552+9.2%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.